Relevance of liposomal amphotericin B in the treatment of invasive fungal infections in patients with hematologic malignancies

被引:1
|
作者
Garcia-Vidal, Carolina [1 ]
Vazquez, Lourdes [2 ]
Jarque, Isidro [3 ]
机构
[1] Hosp Clin Barcelona, Serv Enfermedades Infecciosas, Barcelona, Spain
[2] Hosp Univ, Serv Hematol, Salamanca, Spain
[3] Hosp Univ & Politecn La Fe, Serv Hematol, Valencia, Spain
来源
REVISTA IBEROAMERICANA DE MICOLOGIA | 2021年 / 38卷 / 02期
关键词
Invasive fungal infection; Breakthrough fungal infection; Hematologic malignancies; EMPIRICAL ANTIFUNGAL THERAPY; CELL TRANSPLANT RECIPIENTS; SINGLE-CENTER; PERSISTENT FEVER; AMBISOME THERAPY; MOLD INFECTIONS; PROPHYLAXIS; POSACONAZOLE; EPIDEMIOLOGY; MUCORMYCOSIS;
D O I
10.1016/j.riam.2021.03.001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Liposomal amphotericin B (L-AmB) has been a key cornerstone for the management of invasive fungal infections (IFI) caused by a wide array of molds and yeasts during the last three decades. Multiple studies performed over this period have generated a large body of evidence on its efficacy and safety, becoming the main antifungal agent in the management of IFI in patients with hematologic malignancies in several not mutually exclusive clinical settings. First, L-AmB is the most commonly used antifungal agent in patients undergoing intensive chemotherapy for acute leukemia and high-risk myelodysplastic syndrome, as well as in hematopoietic stem cell transplant recipients. Additionally, due to the administration of newer targeted therapies ( such as monoclonal antibodies or small molecule inhibitors), opportunistic mold infections are increasingly being reported in patients with hematologic malignancies usually considered low-risk for IFI. These agents usually have a high drug-drug interaction potential, being triazoles, commonly used for antifungal prophylaxis, included. Finally, patients developing breakthrough IFI because of either subtherapeutic concentrations of antifungal prophylactic drugs in blood or selection of resistant strains, require broad spectrum antifungal therapy, usually with an antifungal of a different class. In both situations, L-AmB remains as the best option for early antifungal therapy. (C) 2021 Asociacion Espafiola de Micologia. Published by Elsevier Espafia, S.L.U. All rights reserved.
引用
收藏
页码:61 / 67
页数:7
相关论文
共 50 条
  • [1] LIPOSOMAL AMPHOTERICIN-B IN THE TREATMENT OF SYSTEMIC FUNGAL-INFECTIONS IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
    LOPEZBERESTEIN, G
    KEATING, MJ
    BODEY, GP
    [J]. LEUKEMIA, 1987, 1 (03) : 279 - 279
  • [2] Weekly liposomal amphotericin B as secondary prophylaxis for invasive fungal infections in patients with hematological malignancies
    Cahuayme-Zuniga, Lizbeth
    Lewis, Russell E.
    Mulanovich, Victor E.
    Kontoyiannis, Dimitrios P.
    [J]. MEDICAL MYCOLOGY, 2012, 50 (05) : 543 - 548
  • [3] Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: A retrospective, nonrandomized autopsy study
    Chamilos, Georgios
    Luna, Mario
    Lewis, Russell E.
    Chemaly, Roy
    Raad, Issam I.
    Kontoyiannis, Dimitrios P.
    [J]. CLINICAL THERAPEUTICS, 2007, 29 (09) : 1980 - 1986
  • [4] Diagnosis and Treatment of Invasive Fungal Infections Focus on Liposomal Amphotericin B
    Lacerda, Joao F.
    Oliveira, Carlos Meneses
    [J]. CLINICAL DRUG INVESTIGATION, 2013, 33 : S5 - S14
  • [5] Diagnosis and Treatment of Invasive Fungal Infections Focus on Liposomal Amphotericin B
    João F. Lacerda
    Carlos Meneses Oliveira
    [J]. Clinical Drug Investigation, 2013, 33 : 5 - 14
  • [6] Treatment strategies for invasive fungal infections in patients with hematologic malignancies
    Wemeau, Mathieu
    [J]. HEMATOLOGIE, 2011, 17 (04): : 271 - 276
  • [7] Amphotericin B lipid complex for the treatment of presumed or confirmed fungal infections in immunocompromised patients with hematologic malignancies
    Mehta, J
    Chu, P
    Powles, R
    Kelsey, S
    [J]. DRUGS OF TODAY, 1996, 32 (05) : 417 - 421
  • [8] Amphotericin B lipid complex for the treatment of presumed or confirmed fungal infections in immunocompromised patients with hematologic malignancies
    Mehta, J
    Chu, P
    Powles, R
    Kelsey, S
    [J]. DRUGS OF TODAY, 1996, 32 : 27 - 32
  • [9] Liposomal amphotericin B treatment for neonatal fungal infections
    Scarcella, A
    Pasquariello, MB
    Giugliano, B
    Vendemmia, M
    De Lucia, A
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1998, 17 (02) : 146 - 148
  • [10] Amphotericin B lipid complex (ABLC) for fungal infections in immunocompromised patients with hematologic malignancies
    Mehta, J
    Kelsey, SM
    Chu, P
    Powles, R
    Singhal, S
    Hazel, D
    Newland, AC
    Treleaven, J
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 1000 - 1000